drug
invikafusp alfa
Phase 2updated 6mo agoby Marengo Therapeutics Inc
Phase 2community read0 votes
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
News(1)
- ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2Invikafusp alfa, a first-in-class dual T cell agonist, showed an objective response in various types of cancer, particularly among patients who did not respond to previous checkpoint inhibitor ther…biospace · 24d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that